Simulations Plus Partners with NVIDIA to Accelerate Drug Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 23 2026
0mins
Source: Newsfilter
- AI-Driven Drug Development: Simulations Plus announces a partnership with NVIDIA to build the agentic layer of its Composer platform using the BioNeMo Agent Toolkit, aimed at accelerating model-informed drug development and enhancing biopharma innovation capabilities.
- Scientific Reasoning and Evidence Integration: Composer agents will leverage NVIDIA Nemotron™ Parse to extract information from scientific literature, ensuring researchers can trace recommendations and conclusions back to original data, thereby enhancing research transparency and reliability.
- Accelerating Quantitative Systems Pharmacology: Through the nvQSP initiative, the companies are developing CUDA-optimized ordinary differential equation solvers to enhance the efficiency of computationally intensive simulations, enabling scientists to explore parameter spaces and validate hypotheses more rapidly in complex biological systems.
- Strategic Vision and Market Positioning: The CEO of Simulations Plus states that the introduction of agentic AI will transform how scientists interact with models and data, helping researchers move from questions to insights more efficiently while keeping validated science at the center of decision-making.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLP
Wall Street analysts forecast SLP stock price to rise
5 Analyst Rating
2 Buy
3 Hold
0 Sell
Moderate Buy
Current: 18.280
Low
19.00
Averages
19.00
High
19.00
Current: 18.280
Low
19.00
Averages
19.00
High
19.00
About SLP
Simulations Plus, Inc. specializes in model-informed and artificial intelligence (AI)-accelerated drug development. The Company helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The Company's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Simulations Plus Under Investigation for Investor Losses Potentially Recoverable
- Declining Financial Performance: Simulations Plus maintained its full-year revenue guidance of $90 million to $93 million in its Q2 FY2025 report, but subsequently lowered it to $76 million to $80 million, citing budget cuts and project cancellations, which led to a more than 24% drop in share price.
- Significant Loss Disclosure: In July 2025, the company reported a net loss of $67.3 million, including a $77.2 million non-cash impairment charge, highlighting severe challenges in financial management and project execution, raising concerns about its future profitability.
- Audit Firm Dismissal: The dismissal of Grant Thornton LLP as its independent auditor, which reported unresolved issues regarding financial reporting and internal controls to the SEC, exacerbated investor anxiety and caused shares to decline nearly 26% again.
- Investor Investigation Initiated: Johnson Fistel, PLLP is investigating Simulations Plus on behalf of investors who suffered losses, assessing whether these losses may be recoverable under federal securities laws, indicating potential legal ramifications that could significantly impact the company's future financial health.
See More
Simulations Plus Under Investigation for Investor Losses Potentially Recoverable
- Declining Financial Performance: Simulations Plus maintained its fiscal 2025 revenue guidance at $90 million to $93 million during its Q2 report on April 3, 2025, but subsequently lowered it to $76 million to $80 million on June 11, 2025, due to budget cuts and project cancellations, resulting in a more than 24% drop in share price.
- Significant Loss Disclosure: In July 2025, the company reported a net loss of $67.3 million, which included a $77.2 million non-cash impairment charge, indicating a deteriorating financial condition and raising further investor concerns.
- Auditor Dismissal: The dismissal of Grant Thornton LLP as its independent auditor followed, with the firm informing the SEC of unresolved issues regarding financial reporting, leading to a loss of market confidence and a nearly 26% decline in stock price.
- Investor Investigation Initiated: Johnson Fistel, PLLP is investigating Simulations Plus on behalf of investors who suffered losses, assessing whether these losses may be recoverable under federal securities laws, highlighting the increasing legal risks for the company.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating Arcosa, Inc., Simulations Plus, Inc., AstroNova, Inc., and Fathom Holdings Inc. for potential violations of federal securities laws and fiduciary duties to shareholders, with transaction prices at $150.00, $18.50, $29.00, and 0.2236 shares of Bed Bath & Beyond stock respectively.
- Shareholder Rights Protection: The law firm encourages shareholders to contact them to discuss their rights and options, committing to handle matters on a contingent fee basis, which underscores their focus on safeguarding shareholder interests.
- Potential Financial Benefits: The investigation highlights that insiders may receive substantial financial benefits not available to ordinary shareholders, which could impact the fairness and transparency of the transactions, raising concerns among shareholders regarding the terms of the deals.
- Possibility of Legal Action: Halper Sadeh LLC may seek increased consideration, additional disclosures, or other relief measures to protect shareholders' rights, indicating their proactive involvement in addressing securities fraud and corporate misconduct.
See More
Simulations Plus Under Investigation for Securities Violations
- Investigation Background: Johnson Fistel, PLLP is investigating potential securities law violations by Simulations Plus, Inc., focusing on whether the company made false or misleading statements regarding its financial outlook, reporting practices, and internal controls, which could significantly impact investors.
- Revenue Guidance Cut: On June 11, 2025, Simulations Plus revised its full-year fiscal 2025 revenue guidance down from $90 million to $93 million to a range of $76 million to $80 million, primarily due to market uncertainties affecting pharmaceutical and biotechnology clients, leading to budget cuts and project cancellations.
- Stock Price Volatility: Following the guidance cut, Simulations Plus's stock plummeted over 24%, from $26.44 per share to $20.05 per share; additionally, the company reported a net loss of $67.3 million in its third-quarter results on July 14, 2025, causing the stock to drop nearly 26% again.
- Audit Firm Dismissal: On July 15, 2025, Simulations Plus dismissed Grant Thornton LLP as its independent registered public accounting firm due to unresolved matters related to financial reporting, which further eroded market confidence in the company's internal controls.
See More
Simulations Plus Under Investigation for Securities Violations
- Investigation Background: Johnson Fistel, PLLP is investigating potential securities law violations by Simulations Plus, Inc., focusing on misleading statements regarding the company's financial outlook, reporting practices, and internal controls, which could significantly impact investors.
- Revenue Guidance Cut: On June 11, 2025, Simulations Plus revised its fiscal 2025 revenue guidance down to $76 million to $80 million, primarily due to market uncertainties affecting pharmaceutical and biotechnology clients, leading to a stock price drop of over 24%.
- Significant Financial Loss: On July 14, 2025, Simulations Plus reported a net loss of $67.3 million for the third quarter, translating to a loss of $3.35 per diluted share, which included a $77.2 million non-cash impairment charge, indicating severe deterioration in financial health.
- Audit Firm Dismissal: Simulations Plus dismissed Grant Thornton LLP as its independent auditor, citing unresolved issues related to financial reporting, which contributed to a nearly 26% decline in stock price, raising concerns about corporate governance and financial transparency.
See More
Simulations Plus Under Investigation for Securities Violations
- Investigation Background: Johnson Fistel, PLLP is investigating potential securities law violations by Simulations Plus, Inc., focusing on whether the company made false or misleading statements regarding its financial outlook, reporting practices, and internal controls, which could significantly impact investors.
- Revenue Guidance Cut: On June 11, 2025, Simulations Plus revised its full-year fiscal 2025 revenue guidance down to $76 million to $80 million from $90 million to $93 million, primarily due to market uncertainties affecting pharmaceutical and biotechnology clients, leading to budget cuts and project cancellations.
- Stock Price Volatility: Following the revenue guidance cut, Simulations Plus's stock plummeted over 24%, from $26.44 per share to $20.05 per share; subsequently, on July 14, 2025, after reporting a net loss of $67.3 million, the stock fell nearly 26% again.
- Audit Firm Dismissal: Simulations Plus disclosed on July 14, 2025, that it had dismissed Grant Thornton LLP as its independent auditor due to unresolved issues related to financial reporting and internal controls, raising further concerns among investors about the company's financial integrity.
See More
Simulations Plus Under Investigation for Investor Losses Potentially Recoverable
- Declining Financial Performance: Simulations Plus maintained its full-year revenue guidance of $90 million to $93 million in its Q2 FY2025 report, but subsequently lowered it to $76 million to $80 million, citing budget cuts and project cancellations, which led to a more than 24% drop in share price.
- Significant Loss Disclosure: In July 2025, the company reported a net loss of $67.3 million, including a $77.2 million non-cash impairment charge, highlighting severe challenges in financial management and project execution, raising concerns about its future profitability.
- Audit Firm Dismissal: The dismissal of Grant Thornton LLP as its independent auditor, which reported unresolved issues regarding financial reporting and internal controls to the SEC, exacerbated investor anxiety and caused shares to decline nearly 26% again.
- Investor Investigation Initiated: Johnson Fistel, PLLP is investigating Simulations Plus on behalf of investors who suffered losses, assessing whether these losses may be recoverable under federal securities laws, indicating potential legal ramifications that could significantly impact the company's future financial health.
See More
Simulations Plus Under Investigation for Investor Losses Potentially Recoverable
- Declining Financial Performance: Simulations Plus maintained its fiscal 2025 revenue guidance at $90 million to $93 million during its Q2 report on April 3, 2025, but subsequently lowered it to $76 million to $80 million on June 11, 2025, due to budget cuts and project cancellations, resulting in a more than 24% drop in share price.
- Significant Loss Disclosure: In July 2025, the company reported a net loss of $67.3 million, which included a $77.2 million non-cash impairment charge, indicating a deteriorating financial condition and raising further investor concerns.
- Auditor Dismissal: The dismissal of Grant Thornton LLP as its independent auditor followed, with the firm informing the SEC of unresolved issues regarding financial reporting, leading to a loss of market confidence and a nearly 26% decline in stock price.
- Investor Investigation Initiated: Johnson Fistel, PLLP is investigating Simulations Plus on behalf of investors who suffered losses, assessing whether these losses may be recoverable under federal securities laws, highlighting the increasing legal risks for the company.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating Arcosa, Inc., Simulations Plus, Inc., AstroNova, Inc., and Fathom Holdings Inc. for potential violations of federal securities laws and fiduciary duties to shareholders, with transaction prices at $150.00, $18.50, $29.00, and 0.2236 shares of Bed Bath & Beyond stock respectively.
- Shareholder Rights Protection: The law firm encourages shareholders to contact them to discuss their rights and options, committing to handle matters on a contingent fee basis, which underscores their focus on safeguarding shareholder interests.
- Potential Financial Benefits: The investigation highlights that insiders may receive substantial financial benefits not available to ordinary shareholders, which could impact the fairness and transparency of the transactions, raising concerns among shareholders regarding the terms of the deals.
- Possibility of Legal Action: Halper Sadeh LLC may seek increased consideration, additional disclosures, or other relief measures to protect shareholders' rights, indicating their proactive involvement in addressing securities fraud and corporate misconduct.
See More
Simulations Plus Under Investigation for Securities Violations
- Investigation Background: Johnson Fistel, PLLP is investigating potential securities law violations by Simulations Plus, Inc., focusing on whether the company made false or misleading statements regarding its financial outlook, reporting practices, and internal controls, which could significantly impact investors.
- Revenue Guidance Cut: On June 11, 2025, Simulations Plus revised its full-year fiscal 2025 revenue guidance down from $90 million to $93 million to a range of $76 million to $80 million, primarily due to market uncertainties affecting pharmaceutical and biotechnology clients, leading to budget cuts and project cancellations.
- Stock Price Volatility: Following the guidance cut, Simulations Plus's stock plummeted over 24%, from $26.44 per share to $20.05 per share; additionally, the company reported a net loss of $67.3 million in its third-quarter results on July 14, 2025, causing the stock to drop nearly 26% again.
- Audit Firm Dismissal: On July 15, 2025, Simulations Plus dismissed Grant Thornton LLP as its independent registered public accounting firm due to unresolved matters related to financial reporting, which further eroded market confidence in the company's internal controls.
See More
Simulations Plus Under Investigation for Securities Violations
- Investigation Background: Johnson Fistel, PLLP is investigating potential securities law violations by Simulations Plus, Inc., focusing on misleading statements regarding the company's financial outlook, reporting practices, and internal controls, which could significantly impact investors.
- Revenue Guidance Cut: On June 11, 2025, Simulations Plus revised its fiscal 2025 revenue guidance down to $76 million to $80 million, primarily due to market uncertainties affecting pharmaceutical and biotechnology clients, leading to a stock price drop of over 24%.
- Significant Financial Loss: On July 14, 2025, Simulations Plus reported a net loss of $67.3 million for the third quarter, translating to a loss of $3.35 per diluted share, which included a $77.2 million non-cash impairment charge, indicating severe deterioration in financial health.
- Audit Firm Dismissal: Simulations Plus dismissed Grant Thornton LLP as its independent auditor, citing unresolved issues related to financial reporting, which contributed to a nearly 26% decline in stock price, raising concerns about corporate governance and financial transparency.
See More
Simulations Plus Under Investigation for Securities Violations
- Investigation Background: Johnson Fistel, PLLP is investigating potential securities law violations by Simulations Plus, Inc., focusing on whether the company made false or misleading statements regarding its financial outlook, reporting practices, and internal controls, which could significantly impact investors.
- Revenue Guidance Cut: On June 11, 2025, Simulations Plus revised its full-year fiscal 2025 revenue guidance down to $76 million to $80 million from $90 million to $93 million, primarily due to market uncertainties affecting pharmaceutical and biotechnology clients, leading to budget cuts and project cancellations.
- Stock Price Volatility: Following the revenue guidance cut, Simulations Plus's stock plummeted over 24%, from $26.44 per share to $20.05 per share; subsequently, on July 14, 2025, after reporting a net loss of $67.3 million, the stock fell nearly 26% again.
- Audit Firm Dismissal: Simulations Plus disclosed on July 14, 2025, that it had dismissed Grant Thornton LLP as its independent auditor due to unresolved issues related to financial reporting and internal controls, raising further concerns among investors about the company's financial integrity.
See More
